All In Biotech

Drug Trial Radar · NCT03328078

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

152

Planned (sponsor's estimate)

Start

Dec 28, 2017

Primary completion

Jul 2027

Study completion Oct 2027

Sponsor

Lead sponsor
Curis, Inc.Industry
Sponsor type
Industry
First posted
Nov 1, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, open-label study to evaluate the safety, pharmacokinetics (PK), and anti-cancer activity of oral administration of emavusertib alone or in combination with ibrutinib in adult participants with relapsed or refractory (R/R) hematologic malignancies. This trial will be completed in four parts. In Part A1, emavusertib will be evaluated first in a dose escalating monotherapy setting to establish the safety and tolerability (complete). In Part A2, emavusertib will be evaluated in combination with ibrutinib at 560 milligrams (mg) once daily (QD) or 420 mg QD as indicated by disease (Part A2 complete). Part B will comprise 2 cohorts to assess safety and efficacy of emavusertib in combination with ibrutinib in participants with R/R primary central nervous system lymphoma (PCNSL) who have directly progressed on a bruton tyrosine kinase inhibitor (BTKi). In this part of the study, emavusertib will be dosed at 100 mg or 200 mg twice daily (BID) in combination with ibrutinib in 28-day treatment cycles. Part C will comprise 3 treatment arms in the second-line setting to assess the efficacy and safety of emavusertib monotherapy, ibrutinib monotherapy, and emavusertib in combination with ibrutinib in participants with R/R PCNSL who are naïve to BTKi treatment. In this part of the study, eligible second-line participants with R/R PCNSL who are naïve to BTKi treatment will be randomized 1:1:1 to 1 of 3 treatment arms: (1) emavusertib 200 mg BID, (2) ibrutinib 560 mg QD, or (3) emavusertib 200 mg BID in combination with ibrutinib 560 mg QD.

Conditions

  • Relapsed Hematologic Malignancy
  • Refractory Hematologic Malignancy
  • Relapsed Primary Central Nervous System Lymphoma
  • Refractory Primary Central Nervous System Lymphoma

Interventions

  • EmavusertibDrug

    Emavusertib will be provided as a tablet dosage form to be taken BID.

  • IbrutinibDrug

    Ibrutinib will be provided as a tablet or capsule dosage form to be taken QD.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: To determine the safety and tolerability of emavusertib as a monotherapy and in combination with ibrutinib: dose-limiting toxicity (DLT)Time frame: 12 months
  2. Part A: Maximum tolerated dose (MTD) of emavusertib as a monotherapy and in combination with ibrutinib measured by dose-limiting toxicities (DLTs)Time frame: 12 months
  3. Part A: Recommended Phase 2 Dose (RP2D) of emavusertib as a monotherapy and in combination with ibrutinib based on overall tolerability dataTime frame: 12 months
  4. Part B: Overall Response Rate (ORR) in participants with R/R PCNSLTime frame: 18 months
  5. Part C: ORR in participants with R/R PCNSLTime frame: 18 months

Locations

45 sites in 7 countries. Site status is shown where the registry gives one.

  • St. Joseph's Hospital and Medical Center

    Phoenix, Arizona · Recruiting

  • Mayo Clinic

    Phoenix, Arizona · Completed

  • City of Hope

    Duarte, California · Recruiting

  • Providence St. John's Health Center

    Santa Monica, California · Recruiting

  • UCLA Department of Medicine - Hematology/Oncology

    Santa Monica, California · Withdrawn

  • Smilow Cancer Hospital at Yale-New Haven

    New Haven, Connecticut · Completed

  • Mayo Clinic

    Jacksonville, Florida · Recruiting

  • Northwestern Memorial Hospital

    Chicago, Illinois · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • Fred and Pamela Buffett Cancer Center

    Omaha, Nebraska · Recruiting

  • Hackensack University Medical Center

    Hackensack, New Jersey · Completed

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York · Recruiting

  • Mt Sinai

    New York, New York · Recruiting

  • Columbia University Irving Medical Center

    New York, New York · Withdrawn

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Duke University Medical Center, Duke Cancer Center

    Durham, North Carolina · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • Providence Neurological Specialties West

    Portland, Oregon · Recruiting

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania · Completed

  • UPMC Hilman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

  • University of Tennessee Medical Center

    Knoxville, Tennessee · Completed

  • UT Southwestern Medical Center

    Dallas, Texas · Active not recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Huntsman Cancer Institute, University of Utah

    Salt Lake City, Utah · Recruiting

  • Swedish Cancer Institute

    Seattle, Washington · Completed

  • University of Washington Medical Center

    Seattle, Washington · Recruiting

  • Všeobecná fakultní nemocnice v Praze

    Prague, Czechia · Recruiting

  • Institut Bergonie

    Bordeaux, France · Recruiting

  • Hopital de la Timone

    Marseille, France · Recruiting

  • Hospital Pitie Salpetriere

    Paris, France · Recruiting

  • Institut Curie Hospital

    Paris, France · Recruiting

  • Hematology Department Soroka UMC / Heanatology Department

    Beersheba, Israel · Recruiting

  • Rambam Medical Center

    Haifa, Israel · Recruiting

  • Hadassah Medical Center / Ein-Carem

    Jerusalem, Israel · Recruiting

  • Università di Torino Croce e Carle

    Cuneo, Italy · Recruiting

  • SODc Ematologia Azienda Ospedaliera Universitaria Careggi

    Florence, Italy · Recruiting

  • IRST - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

    Meldola, Italy · Recruiting

  • IRCCS San Raffaele Scientific Institute

    Milan, Italy · Recruiting

  • Uniwersyteckie Centrum Kliniczne Osrodek Badan Klinicznych Wczesnych Faz

    Gdansk, Poland · Recruiting

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.